🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials

  2. KAI-9531, KAI-9531, Identical to kai-9531 solution for injection without active drug, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  3. KALOMIN™ Tab.

    United Therapeutics Europe Ltd

    Acute Bronchitis

    phase 3 small molecule completed

    1 trial

  4. KARDEGIC 75 mg, poudre pour solution buvable en sachet-dose, CLOPIDOGREL, CLOPIDOGREL

    ISTA Pharma Limited

    chronically occluded coronary artery

    phase 3 small molecule active

    1 trial

  5. KB803

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  6. KETAMINE RENAUDIN 50 mg/ml, solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    Disc Medicine

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    phase 3 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 734506

    Wuhan Createrna Science and Technology Co., Ltd

    Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

    phase 3 small molecule active

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, JNJ-42756493, JNJ-42756493, JNJ-42756493, Docetaxel-ratiopharm 20mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Janssen-Cilag International N.V.

    Advanced Urothelial Cancer

    phase 3 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  12. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMBROLIZUMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline bag, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp Alfa, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp A

    Bicara Therapeutics

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    phase 3 small molecule active

    1 trial

  13. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, PEMETREXED, INFLIXIMAB, Rilvegostomig, PEMETREXED, CISPLATIN, CARBOPLATIN

    AstraZeneca AB

    Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

  14. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. KIOVIG 100 mg/ml solution for infusion, TECVAYLI 90 mg/mL solution for injection, TECVAYLI 10 mg/mL solution for injection, KIOVIG 100 mg/ml solution for infusion

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  16. KP415 oral capsule

    ZEVRA THERAPEUTICS, INC.

    ADHD

    phase 3 small molecule completed

    2 trials

  17. KVD900 150 mg

    ISTA Pharma Limited

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  18. KVD900 150 mg

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  19. KVD900 600 mg

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 3 small molecule active

    2 trials

  20. KVD900, KVD900

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  21. KVD900, KVD900

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  22. KYV-101

    Kyverna Therapeutics

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial

  23. Kalydeco 75 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, Kalydeco 59.5 mg granules in sachet, VX-445/VX-661/VX-770 film-coated fixed-dose combination tablet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-121/VX-661/VX-561 granules, VX-445/VX-661/VX-770 fixed-dose combination tablet, VX-121/VX-661/VX-561 Film-coated tablet, VX-121/VX-661/VX-561

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  24. Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources